The Revici Foundation For Lipid Biomedical Research, Inc.

MISSION

The Revici Foundation For Lipid Biomedical Research, a nonprofit corporation, encourages scientists to advance the medical innovations of Dr. Emanuel Revici: it also disseminates data generated by his findings in lipid biochemistry.

Born in Romania in 1896, and educated at the Medical School of the University of Bucharest (1914-20), Dr. Revici is the most eminent alternative research clinician in the world. Through seven decades of practice, using lipid-based therapeutic agents created by him, he's saved or prolonged the lives of thousands of patients suffering from cancer, AIDS, and other grave illnesses.

As a scientist and pioneer in nontoxic chemotherapy, he's contributed a host of revolutionary ideas and discoveries since first exploring the relationship of lipids to disease in the 1920s. Four decades later, the D. Van Nostrand Co. (Princeton, NJ), published most of his fundamental concepts and findings in a 780-page text, Research in Physiopathology as Basis of Guided Chemotherapy. Only in the present decade, however, have researchers begun hotly to pursue therapeutic approaches opened by him a generation or two ago.

The Revici Foundation primarily supports research and development of therapies that safely control major life-threatening or chronic debilitating conditions for which no generally effective treatment exists. This research includes: The role of lipids in managing disease; immuno-augmentative therapy; guided vaccine therapy; and adjuvant nutritional therapy.

Equally important, The Revici Foundation responds to the dilemma facing patients who suffer from terminal or disabling diseases resistant to mainstream care. Most of these patients have little understanding of how difficult it is to find beneficial care. Most are also unaware of alternative treatments which do appear effective (and safe), but have not undergone clinical trial (and thus are largely unavailable through mainstream providers of care). Why have these therapies not undergone evaluation? The basic reason: Their originators have lacked the funds to submit the huge amount of data required for approval by the FDA or acceptance by the general medical community.

The Revici Foundation, therefore, appeals to individuals, foundations, and other organizations to (1), help fund the collection of these requisite data and (2), cover the expense of conducting clinical trials of non-invasive innovative therapy.

Please note: Donations to The Revici Foundation are tax-deductible.

Emanuel Revici, MD: Scientific Findings A Method Of Treatment

Dr. Emanuel Revici has devoted nearly 80 years to clinical research on fatty acids, sterols, and the effects of lipids in physiopathology. (Fatty acids and sterols comprise the basic classes of lipid substances.)

Early in his career, he theorized that pathological conditions may be divided into two categories: diseases predominantly anabolic in nature (involving constructive processes); diseases predominantly catabolic in nature (involving destructive processes). The analytic and therapeutic methods he's devised subsequently call for first identifying the predominant "imbalance," then giving catabolic agents (fatty acids and fatty acid derivatives) for anabolic conditions, and anabolic agents (sterols and sterol derivatives) for catabolic ones. His principal theory, which he terms "Biological Dualism," thus allows treatment of many different pathologies with a core group of compounds.

Four conditions (besides cancer and AIDS), exemplify his application of "Dualism." All are widespread or potentially so, all are potentially fatal. Approved and commonly accepted treatments for them appear inferior to his (and can cause harmful complications).

ADDICTION. Dr. Revici hypothesized that alcohol, drug, and nicotine addictions are anabolic in nature, hence treatable by catabolic agents. Between 1970- he administered lipid-based selenium and sulfur compounds to 3,000 heroin addicts, physically detoxifying the vast majority without withdrawal symptoms.

ARTERIOSCLEROSIS. He's prevented and counteracted arteriosclerosis with several catabolic agents. The most active agent seems to be magnesium thiosulfate.

HEMORRHAGE. He's given n-Butanol, a sterol and higher alcohol to stem bleeding from various causes. He published impressive results in severely-bleeding cancer patients too ill for surgical intervention in Angiology (Vol 4, No 6, December 1953).

RADIATION INJURY. He's healed individuals exposed to heavy radiation with anabolic preparations. His paper, "The Influence of Irradiation upon Unsaturated Fatty Acids," delivered before the Sixth Annual Congress of Radiology in London in 1950, shows that abnormally-conjugated trienic fatty acids induce radiation illness. (These are the same substances described under the term "leukotrienes" in an article by Bengt Samuelsson, published decades after the reading of Revici's paper: Samuelsson gained a Nobel Prize in 1982.)

Dr. Mark Noble, Professor of Oncology, University of Utah, visited Dr. Revici in December 1996. Afterward, he wrote about his interest in Revici's research:

"Lipid biology has been relatively unexplored in the world of molecular biology. I am investing my time in studying Dr. Revici's work because I think there is a significant chance that he has created a coherent chain of scientific discoveries. If Dr. Revici's insights are only partially correct, they are of great importance. If even a significant fraction of his work is correct, the repercussions may be enormous."